Skip to main content

Anti-platelets in diabetes management

Buy Article:

$51.00 plus tax (Refund Policy)



This study aimed to determine the prevalence of anti-platelet use, and the extent to which contraindications to anti-platelet therapy prevent its use, in 726 diabetic patients attending a private clinic. Among those who reported a history of cardiovascular disease (CVD), 87.1% were on anti-platelet therapy. Of those without prior CVD but with at least one CVD risk factor, 59.8% were not on anti-platelet therapy, but only 7.1% of these had a contraindication to anti-platelet therapy. This study showed that high usage of anti-platelet therapy in diabetic patients with prior CVD is achievable, and that contraindications did not explain low use in those without prior CVD.

Keywords: aspirin; cardiovascular disease; complications; diabetes mellitus; prevention and control; type 2

Document Type: Research Article


Affiliations: 1: Baker IDI Heart and Diabetes Institute, and 2: Murdoch Children's Research Institute, Melbourne, Victoria, Australia

Publication date: 2010-06-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more